M
Michael S. Hwang
Researcher at Johns Hopkins University School of Medicine
Publications - 15
Citations - 440
Michael S. Hwang is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Antigen & Cancer. The author has an hindex of 6, co-authored 12 publications receiving 156 citations. Previous affiliations of Michael S. Hwang include Johns Hopkins University & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Targeting a neoantigen derived from a common TP53 mutation
Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Katharine M. Wright,Katharine M. Wright,Jacqueline Douglass,Jacqueline Douglass,Michael S. Hwang,Michael S. Hwang,Brian J. Mog,Alexander H. Pearlman,Alexander H. Pearlman,Suman Paul,Sarah R. DiNapoli,Sarah R. DiNapoli,Maximilian F. Konig,Qing Wang,Qing Wang,Annika Schaefer,Annika Schaefer,Michelle S. Miller,Michelle S. Miller,Andrew D. Skora,Andrew D. Skora,P. Aitana Azurmendi,P. Aitana Azurmendi,Michael B. Murphy,Liu Qiang,Liu Qiang,Evangeline Watson,Evangeline Watson,Yana Li,Drew M. Pardoll,Chetan Bettegowda,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Sandra B. Gabelli,Shibin Zhou +37 more
TL;DR: In this paper, the authors describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen-A (HLA-A) allele on the cell surface.
Journal ArticleDOI
Bispecific antibodies targeting mutant RAS neoantigens.
Jacqueline Douglass,Jacqueline Douglass,Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Brian J. Mog,Michael S. Hwang,Michael S. Hwang,Sarah R. DiNapoli,Sarah R. DiNapoli,Alexander H. Pearlman,Alexander H. Pearlman,Michelle S. Miller,Michelle S. Miller,Katharine M. Wright,Katharine M. Wright,P. Aitana Azurmendi,P. Aitana Azurmendi,Qing Wang,Qing Wang,Suman Paul,Annika Schaefer,Annika Schaefer,Andrew D. Skora,Andrew D. Skora,Marco Dal Molin,Marco Dal Molin,Maximilian F. Konig,Liu Qiang,Liu Qiang,Evangeline Watson,Evangeline Watson,Yana Li,Michael B. Murphy,Drew M. Pardoll,Chetan Bettegowda,Nickolas Papadopoulos,Sandra B. Gabelli,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +39 more
TL;DR: In this article, single-chain variable fragments (scFvs) were used to identify peptides derived from recurrent RAS mutations, G12V and Q61H/L/R, in the context of two common human leukocyte antigen (HLA) alleles.
Journal ArticleDOI
Targeting public neoantigens for cancer immunotherapy.
Alexander H. Pearlman,Alexander H. Pearlman,Michael S. Hwang,Maximilian F. Konig,Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Jacqueline Douglass,Jacqueline Douglass,Sarah R. DiNapoli,Sarah R. DiNapoli,Brian J. Mog,Chetan Bettegowda,Drew M. Pardoll,Sandra B. Gabelli,Nicholas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +17 more
TL;DR: The opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them are reviewed.
Journal ArticleDOI
Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes
Andrew D. Skora,Jacqueline Douglass,Michael S. Hwang,Ada J. Tam,Richard L. Blosser,Sandra B. Gabelli,Jianhong Cao,Luis A. Diaz,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +11 more
TL;DR: An approach to identify single-chain variable fragments specific for mutant peptides presented on the cell surface by HLA molecules and demonstrates that these scFvs can be successfully converted to full-length antibodies, termed MANAbodies, targeting “Mutation-Associated Neo-Antigens” bound to HLA.
Journal ArticleDOI
Targeting loss of heterozygosity for cancer-specific immunotherapy
Michael S. Hwang,Brian J. Mog,Brian J. Mog,Jacqueline Douglass,Alexander H. Pearlman,Emily Han-Chung Hsiue,Suman Paul,Sarah R. DiNapoli,Maximilian F. Konig,Drew M. Pardoll,Sandra B. Gabelli,Chetan Bettegowda,Nickolas Papadopoulos,Bert Vogelstein,Shibin Zhou,Kenneth W. Kinzler +15 more
TL;DR: In this article, a proof-of-concept approach utilizing engineered T cells approximating NOT-gate Boolean logic to target counterexpressed antigens resulting from clonal loss of heterozygosity (LOH) events in cancer was proposed.